![John Lewicki](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 31 932 $ in data 31/05/2026
Dr. John A. Lewicki is a Chief Scientific Officer at Mereo BioPharma Group Plc.
Dr. Lewicki was previously employed as a President, Chief Executive Officer & Director by OncoMed Pharmaceuticals, Inc. and a Principal by Scios, Inc. He received his doctorate degree from the University of California San Diego.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/02/2026 | 464.130 ( 0,06% ) | 31 932 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MEREO BIOPHARMA GROUP PLC | Direttore Tecnico/Scientifico/R&S | 01/07/2020 |
| Società | Posizione | Fine |
|---|---|---|
| ONCOMED PHARMACEUTICALS INC | Amministratore Delegato | 23/04/2019 |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures & commercializes pharmaceuticals | Direttore Tecnico/Scientifico/R&S | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures & commercializes pharmaceuticals | Health Technology |
Mereo BioPharma 5, Inc.
 Mereo BioPharma 5, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer stem cell therapeutics | Health Technology |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mereo BioPharma Group Plc
 Mereo BioPharma Group Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
